Rochelle Naylor to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Rochelle Naylor has written about Diabetes Mellitus, Type 2.
Connection Strength
3.302
-
The Impact of Biomarker Screening and Cascade Genetic Testing on the Cost-Effectiveness of MODY Genetic Testing. Diabetes Care. 2019 12; 42(12):2247-2255.
Score: 0.339
-
Pediatric Monogenic Diabetes: A Unique Challenge and Opportunity. Pediatr Ann. 2019 Aug 01; 48(8):e319-e325.
Score: 0.335
-
GCK-MODY in the US Monogenic Diabetes Registry: Description of 27 unpublished variants. Diabetes Res Clin Pract. 2019 May; 151:231-236.
Score: 0.330
-
Economics of Genetic Testing for Diabetes. Curr Diab Rep. 2019 03 27; 19(5):23.
Score: 0.327
-
Management and pregnancy outcomes of women with GCK-MODY enrolled in the US Monogenic Diabetes Registry. Acta Diabetol. 2019 Apr; 56(4):405-411.
Score: 0.321
-
Clinical Management of Women with Monogenic Diabetes During Pregnancy. Curr Diab Rep. 2018 02 15; 18(3):12.
Score: 0.303
-
Adolescent non-adherence reveals a genetic cause for diabetes. Diabet Med. 2015 Jun; 32(6):e20-3.
Score: 0.251
-
Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care. 2014; 37(1):202-9.
Score: 0.223
-
Who should have genetic testing for maturity-onset diabetes of the young? Clin Endocrinol (Oxf). 2011 Oct; 75(4):422-6.
Score: 0.195
-
GLP-1 RA and dual GIP/GLP-1 RA treatment in MODY: a descriptive case series. BMJ Open Diabetes Res Care. 2025 Apr 23; 13(2).
Score: 0.125
-
High Prevalence of A-ß+ Ketosis-Prone Diabetes in Children with Type 2 Diabetes and Diabetic Ketoacidosis at Diagnosis: Evidence from the Rare and Atypical Diabetes Network (RADIANT). Pediatr Diabetes. 2024; 2024.
Score: 0.115
-
Objective and Subjective Sleep Patterns in Adults With Maturity-Onset Diabetes of the Young (MODY). Diabetes Care. 2023 03 01; 46(3):608-612.
Score: 0.107
-
Diagnosis, treatment and disclosure: A qualitative exploration of participant challenges in a Monogenic Diabetes Registry. Genet Med. 2023 04; 25(4):100019.
Score: 0.107
-
Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2). Diabetes. 2019 08; 68(8):1565-1576.
Score: 0.083
-
Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. Ann Intern Med. 2018 02 06; 168(3):170-178.
Score: 0.075
-
GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated. Acta Diabetol. 2016 Oct; 53(5):703-8.
Score: 0.067